<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03277924</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS-52</org_study_id>
    <nct_id>NCT03277924</nct_id>
  </id_info>
  <brief_title>Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas</brief_title>
  <acronym>ImmunoSarc</acronym>
  <official_title>Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical&#xD;
      trial, with eight cohorts (DDCS, EMC, VS, SFT, CCS, ASPS, UPS, LMS and OS). Nine sites in&#xD;
      Spain, 3 sites in Italy and 1 site in the United Kingdom.&#xD;
&#xD;
      C1 to 6&#xD;
&#xD;
      Objective: To evaluate the efficacy of the sunitinib plus nivolumab combination as measured&#xD;
      by PFSR at 6 months (CS/DDCS, EMC, VS, SFT, CCS cohorts) and at 12 months (ASPS cohort).&#xD;
&#xD;
      Treatment: Adult patients will receive an initial induction phase (IP) from day 1 to day 14&#xD;
      of sunitinib 37.5 mg/day followed by a maintenance phase (MP) of sunitinib 25mg/day&#xD;
      continuously + nivolumab 240mg every 2 weeks. Pediatric patients will receive an initial IP&#xD;
      from day 1 to day 14 of (&lt;18 years) sunitinib at 25 mg/day unless the body surface area (BSA)&#xD;
      of the patient is &gt;1.7. If BSA is &gt;1.7, then sunitinib 37.5 mg/day will be given followed by&#xD;
      a MP of sunitinib 25 mg/day continuously + nivolumab 240 mg every 2 weeks regimen (if weight&#xD;
      ≥40 kg) or sunitinib 25 mg/day continuously + nivolumab 3 mg/kg every 2 weeks regimen (if&#xD;
      weight &lt;40kg). Treatment will continue until disease progression, development of unacceptable&#xD;
      toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.&#xD;
&#xD;
      C 7&#xD;
&#xD;
      Objective: To determine the MTD of the epirubicin + ifosfamide + nivolumab combination in&#xD;
      undifferentiated pleomorphic sarcoma and of the doxorubicin + dacarbazine + nivolumab&#xD;
      combination in leiomyosarcoma.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Cohort 7a dose level 0: Patients will receive epirubicin dose of 60 mg/m2/d, d1 and d2 IV 20&#xD;
      minutes; followed by ifosfamide 3 g/m2/d d1-3, IV 3h with MESNA protection (40% of total dose&#xD;
      of ifosfamide in each administration at 0, 3 and 6 h from ifosfamide initiation). Once&#xD;
      finished Ifosfamide infusion of day 3, nivolumab is administered during 30 minutes, at dose&#xD;
      of 360 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of nivolumab is foreseen&#xD;
      in the absence of progressive disease. If three or more DLTs occur nivolumab dose will be&#xD;
      lowered to dose level -1 where patients will receive epirubicin dose of 60 mg/m2/d, d1 and d2&#xD;
      IV 20 minutes; followed by ifosfamide 3 g/m2/d d1-3, IV 3h with MESNA protection (40% of&#xD;
      total dose of ifosfamide in each administration at 0, 3 and 6 h from ifosfamide initiation).&#xD;
      Once finished Ifosfamide infusion of day 3, nivolumab is administered during 30 minutes, at&#xD;
      dose of 240 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of nivolumab is&#xD;
      foreseen in the absence of progressive disease.&#xD;
&#xD;
      Cohort 7b dose level 0: Patients will receive doxorubicin at dose of 75 mg/m2/d, d1 IV 20&#xD;
      minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes. Dacarbazine is administered also&#xD;
      on day 2 of cycle. Once finished Dacarbazine infusion of day 2, nivolumab is administered for&#xD;
      30 minutes, at dose of 360 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of&#xD;
      nivolumab is foreseen in the absence of progressive disease. If three or more DLTs occur&#xD;
      nivolumab dose will be lowered to dose level -1 where patients will receive doxorubicin at&#xD;
      dose of 75 mg/m2/d, d1 IV 20 minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes.&#xD;
      Dacarbazine is administered also on day 2 of cycle. Once finished dacarbazine infusion of day&#xD;
      2, nivolumab is administered for 30 minutes, at dose of 240 mg IV, Q3W. GCSF support is&#xD;
      mandatory. One-year maintenance of nivolumab is foreseen in the absence of progressive&#xD;
      disease.&#xD;
&#xD;
      C 8&#xD;
&#xD;
      Objectives:To determine the MTD of the MAP + nivolumab combination (phase I). Proportion of&#xD;
      patients achieving good pathological response (phase II)&#xD;
&#xD;
      Treatment dose level 0: In the IP, patients will receive CDDP 120 mg/m2 in 48h IV infusion&#xD;
      (days 1-2) followed by doxorubicin 75 mg/m2 in 48h IV infusion (days 3-4). CDDP and&#xD;
      doxorubicin will be given on days 1-4 and 36-39. Nivolumab administration will start on day 4&#xD;
      at flat dose 240 mg (after the end of doxorubicin), being the following doses administered on&#xD;
      days 18, 39, and 53 (240 mg). HD methotrexate at 12 g/m2 in 2-h infusion will be administered&#xD;
      on days 22, 29, 57, and 64. Surgery will be performed after finishing IP. Adjuvant&#xD;
      chemotherapy will be administered after surgery. During the MP patients will receive&#xD;
      nivolumab on day 210, every two weeks up to day 364. If three or more DLTs occur, then&#xD;
      nivolumab dose level -1 will be activated where patients will receive MAP during the IP (same&#xD;
      as described for level 0), but the dose of nivolumab will be 360 mg on days 4 and 36. Surgery&#xD;
      will be performed after finishing IP. Adjuvant chemotherapy will be administered after&#xD;
      surgery. During the MP patients will receive nivolumab on day 210, every three weeks up to&#xD;
      day 364.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts 1-6:&#xD;
&#xD;
      COHORT 1 - Dedifferentiated Chondrosarcoma (DDCS): For DDCS sample size is obtained for the&#xD;
      primary endpoint of 6-month progression-free survival rate, estimated accrual 24 months. A&#xD;
      6-m PFSR of 40% will be considered not promising whereas of 70% will be considered promising&#xD;
      in this population. With a type I error α of 0.05 and a power of 0.90, 23 patients were&#xD;
      estimated in this cohort. With one arm survival design based on survival probability a&#xD;
      Brookmeyer-Crowley like test is assumed (Brookmeyer, 1982) [65]. If at least 14 cases over&#xD;
      the 23 patients have a 6-m PFSR, then further investigation of the experimental treatment is&#xD;
      warranted.&#xD;
&#xD;
      COHORT 2 - Extraskeletal Myxoid Chondrosarcoma (EMC): For EMC sample size is obtained for the&#xD;
      primary endpoint of 6-month progression-free survival rate, and estimated accrual 24 months.&#xD;
      A 6-m PFSR of 50% will be considered not promising whereas of 80% will be considered&#xD;
      promising in this population. With a type I error α of 0.05 and a power of 0.90, 22 patients&#xD;
      were estimated in this cohort. With Simon's two-stage Minimax design, at least 13 cases over&#xD;
      the 20 first patients (stage 1) should have a 6-m PFSR. Then additional 2 patients would be&#xD;
      accrued up to 22 patients. If at least 15 patients had a 6-m PFSR, further investigation of&#xD;
      the drug is warranted.&#xD;
&#xD;
      COHORT 3 - Vascular sarcomas (VS) (including angiosarcoma, hemangioendothelioma and intimal&#xD;
      sarcomas): For VS sample size is obtained for the primary endpoint of 6-month&#xD;
      progression-free survival rate, and estimated accrual 24 months. A 6-m PFSR of 30% will be&#xD;
      considered not promising whereas of 60% will be considered promising in this population. With&#xD;
      a type I error α of 0.05 and a power of 0.90, 23 patients were estimated in this cohort. With&#xD;
      Simon's two-stage Minimax design, at least 8 cases over the 18 first patients (stage 1)&#xD;
      should have a 6-m PFSR. Then additional 5 patients would be accrued up to 23 patients. If at&#xD;
      least 11 patients had a 6-m PFSR, further investigation of the drug is warranted.&#xD;
&#xD;
      COHORT 4 - Solitary Fibrous Tumor (SFT): For SFT cohort sample size is obtained for the&#xD;
      primary endpoint of 6-month progression-free survival rate by Choi criteria, and estimated&#xD;
      accrual of 24 months. A 6-m PFSR of 35% will be considered not promising whereas of 65% will&#xD;
      be considered promising in this population. With a type I error α of 0.05 and a power of&#xD;
      0.90, 24 patients were estimated in this cohort. With Simon's two-stage Minimax design, at&#xD;
      least 6 cases over the 14 first patients (stage 1) should have a 6-m PFSR. Then additional 10&#xD;
      patients would be accrued up to 24 patients. If at least 13 patients had a 6-m PFSR, further&#xD;
      investigation of the drug is warranted.&#xD;
&#xD;
      COHORT 5 - Alveolar Soft Part Sarcoma (ASPS): For ASPS cohort sample size is obtained for the&#xD;
      primary endpoint of 12-month progression-free survival rate by RECIST criteria, and estimated&#xD;
      accrual 24 months. A 12-m PFSR of 40% will be considered not promising whereas of 75% will be&#xD;
      considered promising in this population. With a type I error α of 0.05 and a power of 0.90,&#xD;
      18 patients were estimated in this cohort. With Simon's two stage Minimax design, at least 7&#xD;
      cases over the 12 first patients (stage 1) should have a 12-m PFSR. Then additional 6&#xD;
      patients would be accrued up to 18 patients. If at least 11 patients had a 12-m PFSR, further&#xD;
      investigation of the drug is warranted.&#xD;
&#xD;
      COHORT 6 - Clear Cell Sarcoma (CCS): For CCS cohort sample size is obtained for the primary&#xD;
      endpoint of 6-month progression-free survival rate by RECIST criteria, and estimated accrual&#xD;
      24 months. A 6-m PFSR of 25% will be considered not promising whereas of 55% will be&#xD;
      considered promising in this population. With a type I error α of 0.05 and a power of 0.90,&#xD;
      23 patients were estimated in this cohort. With Simon's two-stage Minimax design, at least 4&#xD;
      cases over the 13 first patients (stage 1) should have a 6-m PFSR. Then additional 10&#xD;
      patients would be accrued up to 23 patients. If at least 10 patients had a 6-m PFSR, further&#xD;
      investigation of the drug is warranted. An additional 5-7% of patients may be recruited to&#xD;
      compensate for potential unevaluable participants.For the variables that follow binomial&#xD;
      distributions, like the PFS rate and for the categorical variables, frequencies and&#xD;
      percentages will be calculated as well as their confidence interval. If needed, to compare&#xD;
      categorical variables both Chi-square test and Fisher's exact test will be performed.&#xD;
      Besides, Kaplan-Meier estimations will be used for PFS. Where possible, exploratory analysis&#xD;
      will include Cox models to estimate the impact of several factors on PFS.&#xD;
&#xD;
      Cohort 7: This cohort includes a phase 1b study (3+3 design plus expansion cohorts) and&#xD;
      therefore no formal sample size has been calculated. Each subcohort (7a: UPS and 7b: LMS)&#xD;
      will include between 10 and 20 patients respectively (including the expansions).&#xD;
&#xD;
      Cohort 8: A phase I/II is planned for this cohort. For the phase I part, the safety of the&#xD;
      MAP + nivolumab combination will be assessed using a 3+3 design including 6 patients treated&#xD;
      at the recommended phase II dose (RP2D). This phase I could include up to 12 patients&#xD;
      approximately. Regarding the phase II part, for osteosarcoma with metastasis at presentation&#xD;
      and resectable primary tumor, in patients with less than 40 years, sample size is obtained&#xD;
      for the primary endpoint of histological response after 2 MAPs of induction. A proportion of&#xD;
      45% of good histological response (≥90% necrosis) will be considered not promising, whereas&#xD;
      68% will be considered promising in this population. With a type I error α of 0.05 and a&#xD;
      power of 0.80, 31 patients were estimated in this cohort. With Simon's two-stage Minimax&#xD;
      design, at least 7 cases over the 13 first patients (initial part) should have good&#xD;
      histological response. Then, additional 18 eligible patients will be accrued up to 31&#xD;
      patients. If at least 19 patients had good histological response, further investigation of&#xD;
      the drug is warranted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1-6: Progression-free survival rate (PFSR)</measure>
    <time_frame>6 months for CS/DDCS, EMC, VS, SFT, and CCS and 12 months for ASPS</time_frame>
    <description>CS/DDCS, EMC, VS, SFT, and CCS cohorts: 6-month progression-free survival rate (PFSR): Efficacy measured by the PFSR at 6 months according to RECIST 1.1. PFSR at 6 months is defined as the percentage of patients who did not experience progression or death due to any cause since enrollmentuntil month 6 after enrollment.&#xD;
ASPS cohort: 12-month progression-free survival rate (PFSR): Efficacy measured by the PFSR at 12 months according to RECIST 1.1. PFSR at 12 months is defined as the percentage of patients who did not experience progression or death due to any cause since the date of enrollment until month 12 after enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 7: Maximum tolerated dose (MTD)</measure>
    <time_frame>1 year</time_frame>
    <description>The maximum tolerated dose (MTD) of the epirubicin + ifosfamide + nivolumab combination will be determined by assessing adverse events according to CTCAE 5.0 and they will be used for adjusting dose levels according to the dose-limiting toxicities detailed in the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 8: Maximum tolerated dose (MTD)</measure>
    <time_frame>1 year</time_frame>
    <description>The maximum tolerated dose (MTD) of the MAP + nivolumab combination will be determined by assessing adverse events according to CTCAE 5.0 and they will be used for adjusting dose levels according to the dose-limiting toxicities detailed in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6 Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the time between the date of enrollment and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6, 7 and 8 Objective response rate (ORR)</measure>
    <time_frame>2 months</time_frame>
    <description>ORR is defined as the number of subjects with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) divided by the number of response evaluable subjects (according to RECIST 1.1 criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6 Correlation between efficacy and potential predictive biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by finding relationships between clinical efficacy results and translational data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6, 7 and 8 Safety profile: Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Safety profile of the experimental treatment, through assessment of adverse event type, incidence, severity, time of appearance, related causes, as well as physical explorations and laboratory tests. Toxicity will be graded and tabulated by using CTCAE 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6 Clinical outcome</measure>
    <time_frame>At 36 months</time_frame>
    <description>Clinical outcomes of post protocol treatments assessed by observation of such treatments in follow-up stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6 Prognostic and response correlation</measure>
    <time_frame>1 month</time_frame>
    <description>Prognostic and response correlation with neutrophils/platelets; lymphocytes/platelets; andred blood cell distribution width (RDW), by assessing hematology tests at baseline, after 2 weeks (before nivolumab), after 1 month, at progression, and at response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-6 6-month progression-free survival rate (PFSR)</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy measured by the PFSR at 6 months according to RECIST 1.1. PFSR at 6 months is defined as the percentage of patients who did not experience progression or death due to any cause since the date of enrollment until month 6 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 7 Median progression-free survival (mPFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time between the date of enrollment and the date of progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 7 Median overall survival (mOS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the time between the date of enrollment and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 8 Pathological response</measure>
    <time_frame>At month 3</time_frame>
    <description>Measured by percentage of necrosis in surgical specimen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Bone Sarcoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C1-6: Adults, IP d1-14 sunitinib 37.5mg/d then MP sunitinib 25mg/d+nivolumab 240mg ev 2 weeks. Pediatrics, IP d1-14 sunitinib 25mg/d, if BSA&gt;1.7 sunitinib 37.5mg/d and MP sunitinib 25mg/d+nivolumab (dose weight dependent). C7a level 0: Epirubicin 60mg/m2/d, d1,2, ifosfamide 3g/m2/d d1-3 and nivolumab 360mg. 3 or more DLTs level -1 same treatment than in level 0, but nivolumab 240mg. C7b level 0: Doxorubicin 75mg/m2/d, d1, dacarbazine 400mg/m2/d (also on d2) and nivolumab 360mg. 3 or more DLTs level -1 same tratment than in level 0, but nivolumab 240mg. GCSF support is mandatory. 1-year maintenance of nivolumab. C8 level 0: In the IP, CDDP 120mg/m2 (d1-2), doxorubicin 75mg/m2 in (d3-4 and d36-39), nivolumab 240mg (d5), and on d18,39,53 and methotrexate 12g/m2 on d22,29,57,64, surgery and MP with nivolumab on d210, every 2 weeks up to d364. 3 or more DLTs level -1, with nivolumab 360mg on d4,36, surgery and MP with nivolumab on d210, ev 3 weeks up to d364.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 100 MG/10 ML [Opdivo]</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.</description>
    <arm_group_label>Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Cohort 1-6&#xD;
&#xD;
          1. Patients (or legal tutors) must provide written informed consent prior to performance&#xD;
             of study-specific procedures and must be willing to comply with treatment and&#xD;
             follow-up. Informed consent must be obtained prior to start of the screening process.&#xD;
             Procedures conducted as part of the patient's routine clinical management (e.g. blood&#xD;
             count, imaging tests, etc.) and obtained prior to signature of informed consent may be&#xD;
             used for screening or baseline purposes as long as these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          2. Age: 12-80 years.&#xD;
&#xD;
          3. Diagnosis of dedifferentiated chondrosarcoma, extraskeletal myxoid chondrosarcoma,&#xD;
             vascular sarcomas (including angiosarcoma, hemangioendothelioma and intimal sarcomas),&#xD;
             solitary fibrous tumor (excluding dedifferentiated SFT), alveolar soft part sarcoma,&#xD;
             and clear cell sarcoma confirmed by central pathology review.&#xD;
&#xD;
          4. Mandatory paraffin embedded tumor blocks must be provided for all subjects without&#xD;
             exception for biomarker analysis before treatment.&#xD;
&#xD;
          5. Metastatic/locally advanced unresectable disease in progression in the last 6 months&#xD;
             according to RECIST 1.1. Patients with recent diagnosis of metastatic disease can be&#xD;
             eligible (if they are not candidates to anthracycline-based treatment).&#xD;
&#xD;
          6. Patients should have previously received at least anthracyclines. Patients in the&#xD;
             cohorts of subtypes sensitive to antiangiogenic therapy (SFT, ASPS, CCS, EMC or DDCS)&#xD;
             are eligible even if not previously treated.&#xD;
&#xD;
          7. Previous therapy with antiangiogenics is allowed.&#xD;
&#xD;
          8. Measurable disease according to RECIST 1.1 criteria.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
         10. Adequate hepatic, renal, cardiac, and hematologic function.&#xD;
&#xD;
         11. Laboratory tests as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,200/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  PT and INR ≤ 1.5 in the absence of anticoagulant therapy&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL (or Cr clearance ≥ 60 ml/min)&#xD;
&#xD;
               -  Calcium ≤ 12 mg/dL&#xD;
&#xD;
         12. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan.&#xD;
&#xD;
         13. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to enrollment and agree to use birth control measures during study&#xD;
             treatment and for 6 months after its completion. Patients must not be pregnant or&#xD;
             nursing at study entry. Women/men of reproductive potential must have agreed to use an&#xD;
             effective contraceptive method.&#xD;
&#xD;
        Cohort 7&#xD;
&#xD;
          1. The patient or his/her legal tutors must provide written informed consent prior to&#xD;
             performance of study-specific procedures and must be willing to comply with treatment&#xD;
             and follow-up. Informed consent must be obtained prior to start of screening process.&#xD;
             Procedures conducted as part of the patient's routine clinical management (e.g. blood&#xD;
             count, imaging tests, etc.) and obtained prior to signature of informed consent may be&#xD;
             used for screening or baseline purposes as long as these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          2. Age: 18-80 years.&#xD;
&#xD;
          3. Diagnosis of advanced/metastatic undifferentiated pleomorphic sarcoma (UPS) (cohort&#xD;
             7a) or leiomyosarcoma (LMS) (cohort 7b) confirmed by central pathology review.&#xD;
&#xD;
          4. Mandatory pre-treatment formalin-fixed paraffin embedded (FFPE) tumor tissue must be&#xD;
             provided for all subjects without exception for central pathology review and the&#xD;
             translational study. Archive tissue can be used for diagnosis confirmation but a&#xD;
             recent biopsy (&lt;3 months) is mandatory for translational research. If it is not&#xD;
             available or is older than 3 months, the patient must be willing to have a&#xD;
             pre-treatment re-biopsy of primary or metastatic tumor (baseline biopsy) within 28&#xD;
             days prior to enrollment.&#xD;
&#xD;
          5. Measurable disease according to RECIST v1.1 criteria.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          7. The patient must be naïve of any previous treatment with anthracyclines (not even in&#xD;
             adjuvant chemotherapy).&#xD;
&#xD;
          8. Adequate organ, hepatic, renal, cardiac, and hematologic function.&#xD;
&#xD;
          9. Laboratory tests as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Hg &gt; 9 g/dL&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  PT and INR ≤ 1.5&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL or estimated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Blood glucose &lt; 150 mg/dL&#xD;
&#xD;
         10. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan assessed&#xD;
             within 28 days before enrollment.&#xD;
&#xD;
         11. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to enrollment. Patients must not be pregnant or nursing at study&#xD;
             entry.&#xD;
&#xD;
         12. Women and men of reproductive potential must have agreed to use an effective&#xD;
             contraceptive method during study treatment and for 6 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
        Cohort 8&#xD;
&#xD;
          1. The patient or his/her legal tutors must provide written informed consent prior to&#xD;
             performance of study-specific procedures and must be willing to comply with treatment&#xD;
             and follow-up. Informed consent must be obtained prior to start of screening process.&#xD;
             Procedures conducted as part of the patient's routine clinical management (e.g. blood&#xD;
             count, imaging tests, etc.) and obtained prior to signature of informed consent may be&#xD;
             used for screening or baseline purposes as long as these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          2. Age: 12-40 years.&#xD;
&#xD;
          3. Diagnosis of resectable primary metastatic high-grade osteosarcoma confirmed by&#xD;
             central pathology review. Resection of primary tumor +/- metastatic disease has to be&#xD;
             feasible and planned.&#xD;
&#xD;
          4. Mandatory pre-treatment formalin-fixed paraffin embedded (FFPE) tumor tissue must be&#xD;
             provided for all subjects without exception for central pathology review and the&#xD;
             translational study. The patient must be willing to have a pre-treatment re-biopsy of&#xD;
             primary or metastatic tumor (baseline biopsy) within 28 days prior to enrollment if&#xD;
             diagnosis biopsy does not have enough remaining tissue for translational purposes.&#xD;
&#xD;
          5. Measurable disease according to RECIST v1.1 criteria.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          7. The patient must be naïve of any previous treatment.&#xD;
&#xD;
          8. Adequate organ, hepatic, renal, cardiac, and hematologic function.&#xD;
&#xD;
          9. Laboratory tests as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Hg &gt; 9 g/dL&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  PT and INR ≤ 1.5&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL or estimated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Blood glucose &lt; 150 mg/dL&#xD;
&#xD;
         10. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan assessed&#xD;
             within 28 days before enrollment.&#xD;
&#xD;
         11. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to enrollment. Patients must not be pregnant or nursing at study&#xD;
             entry.&#xD;
&#xD;
         12. Women and men of reproductive potential must have agreed to use an effective&#xD;
             contraceptive method during study treatment and for 6 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Cohort 1-6&#xD;
&#xD;
          1. Four or more previous lines of chemotherapy.&#xD;
&#xD;
          2. Previous anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti&#xD;
             PD-L2 or anti CTLA-4 antibody.&#xD;
&#xD;
          3. Prior immune-related adverse event (Grade 3 or higher immune-related pneumonitis,&#xD;
             hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine,&#xD;
             cytokine, etc.).&#xD;
&#xD;
          4. Active, known or suspected autoimmune disease.&#xD;
&#xD;
          5. A condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration. Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness (or within 12 months prior to first dose of study&#xD;
             drug) including (not limited to): symptomatic congestive heart failure (CHF) (New York&#xD;
             Heart Association [NYHA] III/IV), unstable angina pectoris or coronary angioplasty, or&#xD;
             stenting, unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI-CTCAE]&#xD;
             version 5.0 Grade &gt;= 2), known psychiatric illness that would limit study compliance,&#xD;
             intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve&#xD;
             morphology (&gt;= Grade 3).&#xD;
&#xD;
          7. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV antibody) indicating acute or chronic infection.&#xD;
&#xD;
          8. Other disease or illness within the past 12 months, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Coronary or peripheral artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
          9. Evidence of a bleeding diathesis.&#xD;
&#xD;
         10. Uncontrolled hypertension, defined as blood pressure &gt; 150/100 mm Hg despite optimal&#xD;
             medical therapy.&#xD;
&#xD;
         11. Pre-existing thyroid abnormality, defined as abnormal thyroid function tests despite&#xD;
             medication.&#xD;
&#xD;
         12. Prolonged QTc interval (i.e., QTc &gt; 450 msec for males or QTc &gt; 470 msec for females)&#xD;
             on baseline ECG.&#xD;
&#xD;
         13. Hemorrhage ≥ Grade 3 in the past 4 weeks.&#xD;
&#xD;
         14. History of allergy to study drug components.&#xD;
&#xD;
         15. Anticoagulants due to thrombotic events, with the exception of deep venous thrombosis&#xD;
             in limbs, with a stable dose of low-weigh heparine and in the absence of secondary&#xD;
             hemorrages.&#xD;
&#xD;
         16. History of another cancer in the previous 5 years with the exception of adequately&#xD;
             treated squamous or basal cell carcinoma of the skin or cervical cancer in situ.&#xD;
&#xD;
         17. Presence of brain or central nervous system metastases, unless they are controlled&#xD;
             (completely resected or irradiated and/or asympthomatic, no need of steroids).&#xD;
&#xD;
         18. Unwilling to participate in the translational study (not providing mandatory biopsies&#xD;
             at baseline).&#xD;
&#xD;
         19. Live vaccine 30 days or fewer prior to enrollment.&#xD;
&#xD;
        Cohort 7&#xD;
&#xD;
          1. Diagnosis of any sarcoma different from undifferentiated pleomorphic sarcoma and&#xD;
             leiomyosarcoma.&#xD;
&#xD;
          2. Previous treatment with anthracyclines or any other systemic therapy for advanced&#xD;
             sarcoma. The exception is hormone therapy or previous systemic therapy for a previous&#xD;
             neoplasm (see exclusion criteria number 13), if this is controlled as long as previous&#xD;
             therapy did not include anthracyclines. Adjuvant therapy not containing anthracyclines&#xD;
             (eg: gemcitabine-docetaxel) is allowed.&#xD;
&#xD;
          3. Previous anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti&#xD;
             PD-L2 or anti CTLA-4 antibody.&#xD;
&#xD;
          4. Prior immune-related adverse event (Grade 3 or higher immune-related pneumonitis,&#xD;
             hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine,&#xD;
             cytokine, etc.).&#xD;
&#xD;
          5. Active, known or suspected autoimmune disease.&#xD;
&#xD;
          6. A condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration. Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including (not limited to): symptomatic congestive&#xD;
             heart failure (CHF) (New York Heart Association [NYHA] III/IV), unstable angina&#xD;
             pectoris or coronary angioplasty, or stenting within 24 weeks prior to registration,&#xD;
             unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI-CTCAE] version 5.0&#xD;
             Grade &gt;= 2), known psychiatric illness that would limit study compliance,&#xD;
             intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve&#xD;
             morphology (&gt;= Grade 3).&#xD;
&#xD;
          8. HBV and HCV serologies must be preformed prior to inclusion. Positive test for&#xD;
             hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV&#xD;
             antibody) indicating acute or chronic infection is not allowed.&#xD;
&#xD;
          9. Pre-existing thyroid abnormality, defined as abnormal thyroid function tests despite&#xD;
             medication.&#xD;
&#xD;
         10. Any of the following diseases/illnesses within the previous 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Coronary or peripheral artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack (TIA)&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
               -  Evidence of a bleeding diathesis.&#xD;
&#xD;
               -  Ongoing cardiac dysrhythmias &gt; Grade 2.&#xD;
&#xD;
         11. Prolonged QTc interval (i.e., QTc &gt; 450 msec for males or QTc &gt; 470 msec for females)&#xD;
             on baseline ECG.&#xD;
&#xD;
         12. History of allergy to study drug components.&#xD;
&#xD;
         13. History of another cancer with the exception of adequately treated basal cell&#xD;
             carcinoma or in situ cervical cancer, or with a relapse-free interval longer than 3&#xD;
             years after treatment of the primary cancer with no substantial risk of recurrence.&#xD;
&#xD;
         14. Presence of brain or central nervous system metastases at the time of enrollment,&#xD;
             unless they are controlled (completely resected or irradiated and/or asympthomatic, no&#xD;
             need of steroids).&#xD;
&#xD;
         15. Patient is unwilling to provide mandatory translational tumor samples or biopsies (if&#xD;
             required) cannot be easily traken.&#xD;
&#xD;
        Cohort 8&#xD;
&#xD;
          1. Diagnosis of parosteal, periosteal osteosarcoma or any other bone sarcoma.&#xD;
&#xD;
          2. Previous systemic therapy.&#xD;
&#xD;
          3. Previous anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti&#xD;
             PD-L2 or anti CTLA-4 antibody.&#xD;
&#xD;
          4. Prior immune-related adverse event (Grade 3 or higher immune-related pneumonitis,&#xD;
             hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine,&#xD;
             cytokine, etc.).&#xD;
&#xD;
          5. Active, known or suspected autoimmune disease.&#xD;
&#xD;
          6. A condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration. Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including (not limited to): symptomatic congestive&#xD;
             heart failure (CHF) (New York Heart Association [NYHA] III/IV), unstable angina&#xD;
             pectoris or coronary angioplasty, or stenting within 24 weeks prior to registration,&#xD;
             unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI-CTCAE] version 5.0&#xD;
             Grade &gt;= 2), known psychiatric illness that would limit study compliance,&#xD;
             intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve&#xD;
             morphology (&gt;= Grade 3).&#xD;
&#xD;
          8. HBV and HCV serologies must be performed prior to inclusion. Positive test for&#xD;
             hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV&#xD;
             antibody) indicating acute or chronic infection is not allowed.&#xD;
&#xD;
          9. Pre-existing thyroid abnormality, defined as abnormal thyroid function tests despite&#xD;
             medication.&#xD;
&#xD;
         10. Any of the following diseases/illnesses within the previous 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Coronary or peripheral artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack (TIA)&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
               -  Evidence of a bleeding diathesis&#xD;
&#xD;
               -  Ongoing cardiac dysrhythmias &gt; Grade 2.&#xD;
&#xD;
         11. Prolonged QTc interval (i.e., QTc &gt; 450 msec for males or QTc &gt; 470 msec for females)&#xD;
             on baseline ECG.&#xD;
&#xD;
         12. History of allergy to study drug components.&#xD;
&#xD;
         13. History of another cancer with the exception of adequately treated basal cell&#xD;
             carcinoma or in situ cervical cancer, or with a relapse-free interval longer than 3&#xD;
             years after treatment of the primary cancer with no substantial risk of recurrence.&#xD;
&#xD;
         14. Presence of brain or central nervous system metastases at the time of enrollment,&#xD;
             unless they are controlled (completely resected or irradiated and/or asympthomatic, no&#xD;
             need of steroids).&#xD;
&#xD;
         15. Patient is unwilling to provide mandatory translational tumor samples or biopsies (if&#xD;
             required) cannot be easily taken.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martín Broto</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Fundación Jiménez Díaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés Redondo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Valverde</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio López Pousa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Diaz de Beveridge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Martínez Trufero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Carrasco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique González</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josefina Cruz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Stacchiotti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Grignani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Candiolo Cancer Institute - FPO, IRCCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuela Palmerini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Strauss</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Mata</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Casado</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Pérez Fidalgo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis De Sande</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de León</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alba Rubio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infantil Universitario Niño Jesús</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerónimo Martínez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricio Ledesma</last_name>
    <phone>+34 971439900</phone>
    <email>ensayos@sofpromed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Palmerini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Candiolo Cancer Institute - FPO, IRCCS</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad De Madrid</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martín-Broto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Cruz-Jurado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Valverde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio López Pousa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique González</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Carrasco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Díaz de Beveridge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martínez Trufero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Strauss</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2023</verification_date>
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>July 14, 2023</last_update_submitted>
  <last_update_submitted_qc>July 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dedifferentiated chondrosarcoma</keyword>
  <keyword>Extraskeletal myxoid chondrosarcoma</keyword>
  <keyword>Angiosarcoma</keyword>
  <keyword>Hemangioendothelioma</keyword>
  <keyword>Intimal sarcomas</keyword>
  <keyword>Solitary fibrous tumor</keyword>
  <keyword>Clear cell sarcoma</keyword>
  <keyword>Alveolar soft-part sarcoma</keyword>
  <keyword>Undifferentiated pleomorphic sarcoma</keyword>
  <keyword>Leiomyosarcoma</keyword>
  <keyword>Osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03277924
org study id: GEIS-52
nct id: NCT03277924
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
is us export: No
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical
      trial, with eight cohorts (DDCS, EMC, VS, SFT, CCS, ASPS, UPS, LMS and OS). Nine sites in
      Spain, 3 sites in Italy and 1 site in the United Kingdom.

      C1 to 6

      Objective: To evaluate the efficacy of the sunitinib plus nivolumab combination as measured
      by PFSR at 6 months (CS/DDCS, EMC, VS, SFT, CCS cohorts) and at 12 months (ASPS cohort).

      Treatment: Adult patients will receive an initial induction phase (IP) from day 1 to day 14
      of sunitinib 37.5 mg/day followed by a maintenance phase (MP) of sunitinib 25mg/day
      continuously + nivolumab 240mg every 2 weeks. Pediatric patients will receive an initial IP
      from day 1 to day 14 of (<18 years) sunitinib at 25 mg/day unless the body surface area (BSA)
      of the patient is >1.7. If BSA is >1.7, then sunitinib 37.5 mg/day will be given followed by
      a MP of sunitinib 25 mg/day continuously + nivolumab 240 mg every 2 weeks regimen (if weight
      ≥40 kg) or sunitinib 25 mg/day continuously + nivolumab 3 mg/kg every 2 weeks regimen (if
      weight <40kg). Treatment will continue until disease progression, development of unacceptable
      toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

      C 7

      Objective: To determine the MTD of the epirubicin + ifosfamide + nivolumab combination in
      undifferentiated pleomorphic sarcoma and of the doxorubicin + dacarbazine + nivolumab
      combination in leiomyosarcoma.

      Treatment:

      Cohort 7a dose level 0: Patients will receive epirubicin dose of 60 mg/m2/d, d1 and d2 IV 20
      minutes; followed by ifosfamide 3 g/m2/d d1-3, IV 3h with MESNA protection (40% of total dose
      of ifosfamide in each administration at 0, 3 and 6 h from ifosfamide initiation). Once
      finished Ifosfamide infusion of day 3, nivolumab is administered during 30 minutes, at dose
      of 360 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of nivolumab is foreseen
      in the absence of progressive disease. If three or more DLTs occur nivolumab dose will be
      lowered to dose level -1 where patients will receive epirubicin dose of 60 mg/m2/d, d1 and d2
      IV 20 minutes; followed by ifosfamide 3 g/m2/d d1-3, IV 3h with MESNA protection (40% of
      total dose of ifosfamide in each administration at 0, 3 and 6 h from ifosfamide initiation).
      Once finished Ifosfamide infusion of day 3, nivolumab is administered during 30 minutes, at
      dose of 240 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of nivolumab is
      foreseen in the absence of progressive disease.

      Cohort 7b dose level 0: Patients will receive doxorubicin at dose of 75 mg/m2/d, d1 IV 20
      minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes. Dacarbazine is administered also
      on day 2 of cycle. Once finished Dacarbazine infusion of day 2, nivolumab is administered for
      30 minutes, at dose of 360 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of
      nivolumab is foreseen in the absence of progressive disease. If three or more DLTs occur
      nivolumab dose will be lowered to dose level -1 where patients will receive doxorubicin at
      dose of 75 mg/m2/d, d1 IV 20 minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes.
      Dacarbazine is administered also on day 2 of cycle. Once finished dacarbazine infusion of day
      2, nivolumab is administered for 30 minutes, at dose of 240 mg IV, Q3W. GCSF support is
      mandatory. One-year maintenance of nivolumab is foreseen in the absence of progressive
      disease.

      C 8

      Objectives:To determine the MTD of the MAP + nivolumab combination (phase I). Proportion of
      patients achieving good pathological response (phase II)

      Treatment dose level 0: In the IP, patients will receive CDDP 120 mg/m2 in 48h IV infusion
      (days 1-2) followed by doxorubicin 75 mg/m2 in 48h IV infusion (days 3-4). CDDP and
      doxorubicin will be given on days 1-4 and 36-39. Nivolumab administration will start on day 4
      at flat dose 240 mg (after the end of doxorubicin), being the following doses administered on
      days 18, 39, and 53 (240 mg). HD methotrexate at 12 g/m2 in 2-h infusion will be administered
      on days 22, 29, 57, and 64. Surgery will be performed after finishing IP. Adjuvant
      chemotherapy will be administered after surgery. During the MP patients will receive
      nivolumab on day 210, every two weeks up to day 364. If three or more DLTs occur, then
      nivolumab dose level -1 will be activated where patients will receive MAP during the IP (same
      as described for level 0), but the dose of nivolumab will be 360 mg on days 4 and 36. Surgery
      will be performed after finishing IP. Adjuvant chemotherapy will be administered after
      surgery. During the MP patients will receive nivolumab on day 210, every three weeks up to
      day 364.
Cohorts 1-6:

      COHORT 1 - Dedifferentiated Chondrosarcoma (DDCS): For DDCS sample size is obtained for the
      primary endpoint of 6-month progression-free survival rate, estimated accrual 24 months. A
      6-m PFSR of 40% will be considered not promising whereas of 70% will be considered promising
      in this population. With a type I error α of 0.05 and a power of 0.90, 23 patients were
      estimated in this cohort. With one arm survival design based on survival probability a
      Brookmeyer-Crowley like test is assumed (Brookmeyer, 1982) [65]. If at least 14 cases over
      the 23 patients have a 6-m PFSR, then further investigation of the experimental treatment is
      warranted.

      COHORT 2 - Extraskeletal Myxoid Chondrosarcoma (EMC): For EMC sample size is obtained for the
      primary endpoint of 6-month progression-free survival rate, and estimated accrual 24 months.
      A 6-m PFSR of 50% will be considered not promising whereas of 80% will be considered
      promising in this population. With a type I error α of 0.05 and a power of 0.90, 22 patients
      were estimated in this cohort. With Simon's two-stage Minimax design, at least 13 cases over
      the 20 first patients (stage 1) should have a 6-m PFSR. Then additional 2 patients would be
      accrued up to 22 patients. If at least 15 patients had a 6-m PFSR, further investigation of
      the drug is warranted.

      COHORT 3 - Vascular sarcomas (VS) (including angiosarcoma, hemangioendothelioma and intimal
      sarcomas): For VS sample size is obtained for the primary endpoint of 6-month
      progression-free survival rate, and estimated accrual 24 months. A 6-m PFSR of 30% will be
      considered not promising whereas of 60% will be considered promising in this population. With
      a type I error α of 0.05 and a power of 0.90, 23 patients were estimated in this cohort. With
      Simon's two-stage Minimax design, at least 8 cases over the 18 first patients (stage 1)
      should have a 6-m PFSR. Then additional 5 patients would be accrued up to 23 patients. If at
      least 11 patients had a 6-m PFSR, further investigation of the drug is warranted.

      COHORT 4 - Solitary Fibrous Tumor (SFT): For SFT cohort sample size is obtained for the
      primary endpoint of 6-month progression-free survival rate by Choi criteria, and estimated
      accrual of 24 months. A 6-m PFSR of 35% will be considered not promising whereas of 65% will
      be considered promising in this population. With a type I error α of 0.05 and a power of
      0.90, 24 patients were estimated in this cohort. With Simon's two-stage Minimax design, at
      least 6 cases over the 14 first patients (stage 1) should have a 6-m PFSR. Then additional 10
      patients would be accrued up to 24 patients. If at least 13 patients had a 6-m PFSR, further
      investigation of the drug is warranted.

      COHORT 5 - Alveolar Soft Part Sarcoma (ASPS): For ASPS cohort sample size is obtained for the
      primary endpoint of 12-month progression-free survival rate by RECIST criteria, and estimated
      accrual 24 months. A 12-m PFSR of 40% will be considered not promising whereas of 75% will be
      considered promising in this population. With a type I error α of 0.05 and a power of 0.90,
      18 patients were estimated in this cohort. With Simon's two stage Minimax design, at least 7
      cases over the 12 first patients (stage 1) should have a 12-m PFSR. Then additional 6
      patients would be accrued up to 18 patients. If at least 11 patients had a 12-m PFSR, further
      investigation of the drug is warranted.

      COHORT 6 - Clear Cell Sarcoma (CCS): For CCS cohort sample size is obtained for the primary
      endpoint of 6-month progression-free survival rate by RECIST criteria, and estimated accrual
      24 months. A 6-m PFSR of 25% will be considered not promising whereas of 55% will be
      considered promising in this population. With a type I error α of 0.05 and a power of 0.90,
      23 patients were estimated in this cohort. With Simon's two-stage Minimax design, at least 4
      cases over the 13 first patients (stage 1) should have a 6-m PFSR. Then additional 10
      patients would be accrued up to 23 patients. If at least 10 patients had a 6-m PFSR, further
      investigation of the drug is warranted. An additional 5-7% of patients may be recruited to
      compensate for potential unevaluable participants.For the variables that follow binomial
      distributions, like the PFS rate and for the categorical variables, frequencies and
      percentages will be calculated as well as their confidence interval. If needed, to compare
      categorical variables both Chi-square test and Fisher's exact test will be performed.
      Besides, Kaplan-Meier estimations will be used for PFS. Where possible, exploratory analysis
      will include Cox models to estimate the impact of several factors on PFS.

      Cohort 7: This cohort includes a phase 1b study (3+3 design plus expansion cohorts) and
      therefore no formal sample size has been calculated. Each subcohort (7a: UPS and 7b: LMS)
      will include between 10 and 20 patients respectively (including the expansions).

      Cohort 8: A phase I/II is planned for this cohort. For the phase I part, the safety of the
      MAP + nivolumab combination will be assessed using a 3+3 design including 6 patients treated
      at the recommended phase II dose (RP2D). This phase I could include up to 12 patients
      approximately. Regarding the phase II part, for osteosarcoma with metastasis at presentation
      and resectable primary tumor, in patients with less than 40 years, sample size is obtained
      for the primary endpoint of histological response after 2 MAPs of induction. A proportion of
      45% of good histological response (≥90% necrosis) will be considered not promising, whereas
      68% will be considered promising in this population. With a type I error α of 0.05 and a
      power of 0.80, 31 patients were estimated in this cohort. With Simon's two-stage Minimax
      design, at least 7 cases over the 13 first patients (initial part) should have good
      histological response. Then, additional 18 eligible patients will be accrued up to 31
      patients. If at least 19 patients had good histological response, further investigation of
      the drug is warranted.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial
primary purpose: Treatment
masking: None (Open Label)
measure: Cohort 1-6: Progression-free survival rate (PFSR)
time frame: 6 months for CS/DDCS, EMC, VS, SFT, and CCS and 12 months for ASPS
description: CS/DDCS, EMC, VS, SFT, and CCS cohorts: 6-month progression-free survival rate (PFSR): Efficacy measured by the PFSR at 6 months according to RECIST 1.1. PFSR at 6 months is defined as the percentage of patients who did not experience progression or death due to any cause since enrollmentuntil month 6 after enrollment.
ASPS cohort: 12-month progression-free survival rate (PFSR): Efficacy measured by the PFSR at 12 months according to RECIST 1.1. PFSR at 12 months is defined as the percentage of patients who did not experience progression or death due to any cause since the date of enrollment until month 12 after enrollment.
measure: Cohort 7: Maximum tolerated dose (MTD)
time frame: 1 year
description: The maximum tolerated dose (MTD) of the epirubicin + ifosfamide + nivolumab combination will be determined by assessing adverse events according to CTCAE 5.0 and they will be used for adjusting dose levels according to the dose-limiting toxicities detailed in the protocol.
measure: Cohort 8: Maximum tolerated dose (MTD)
time frame: 1 year
description: The maximum tolerated dose (MTD) of the MAP + nivolumab combination will be determined by assessing adverse events according to CTCAE 5.0 and they will be used for adjusting dose levels according to the dose-limiting toxicities detailed in the protocol.
measure: Cohort 1-6 Overall survival (OS)
time frame: 2 years
description: OS is defined as the time between the date of enrollment and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.
measure: Cohort 1-6, 7 and 8 Objective response rate (ORR)
time frame: 2 months
description: ORR is defined as the number of subjects with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) divided by the number of response evaluable subjects (according to RECIST 1.1 criteria).
measure: Cohort 1-6 Correlation between efficacy and potential predictive biomarkers
time frame: 2 years
description: Assessed by finding relationships between clinical efficacy results and translational data.
measure: Cohort 1-6, 7 and 8 Safety profile: Adverse events
time frame: 3 years
description: Safety profile of the experimental treatment, through assessment of adverse event type, incidence, severity, time of appearance, related causes, as well as physical explorations and laboratory tests. Toxicity will be graded and tabulated by using CTCAE 5.0.
measure: Cohort 1-6 Clinical outcome
time frame: At 36 months
description: Clinical outcomes of post protocol treatments assessed by observation of such treatments in follow-up stage.
measure: Cohort 1-6 Prognostic and response correlation
time frame: 1 month
description: Prognostic and response correlation with neutrophils/platelets; lymphocytes/platelets; andred blood cell distribution width (RDW), by assessing hematology tests at baseline, after 2 weeks (before nivolumab), after 1 month, at progression, and at response.
measure: Cohort 1-6 6-month progression-free survival rate (PFSR)
time frame: 6 months
description: Efficacy measured by the PFSR at 6 months according to RECIST 1.1. PFSR at 6 months is defined as the percentage of patients who did not experience progression or death due to any cause since the date of enrollment until month 6 after enrollment.
measure: Cohort 7 Median progression-free survival (mPFS)
time frame: 6 months
description: PFS is defined as the time between the date of enrollment and the date of progression or death due to any cause.
measure: Cohort 7 Median overall survival (mOS)
time frame: 2 years
description: OS is defined as the time between the date of enrollment and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.
measure: Cohort 8 Pathological response
time frame: At month 3
description: Measured by percentage of necrosis in surgical specimen.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
arm group type: Experimental
description: C1-6: Adults, IP d1-14 sunitinib 37.5mg/d then MP sunitinib 25mg/d+nivolumab 240mg ev 2 weeks. Pediatrics, IP d1-14 sunitinib 25mg/d, if BSA>1.7 sunitinib 37.5mg/d and MP sunitinib 25mg/d+nivolumab (dose weight dependent). C7a level 0: Epirubicin 60mg/m2/d, d1,2, ifosfamide 3g/m2/d d1-3 and nivolumab 360mg. 3 or more DLTs level -1 same treatment than in level 0, but nivolumab 240mg. C7b level 0: Doxorubicin 75mg/m2/d, d1, dacarbazine 400mg/m2/d (also on d2) and nivolumab 360mg. 3 or more DLTs level -1 same tratment than in level 0, but nivolumab 240mg. GCSF support is mandatory. 1-year maintenance of nivolumab. C8 level 0: In the IP, CDDP 120mg/m2 (d1-2), doxorubicin 75mg/m2 in (d3-4 and d36-39), nivolumab 240mg (d5), and on d18,39,53 and methotrexate 12g/m2 on d22,29,57,64, surgery and MP with nivolumab on d210, every 2 weeks up to d364. 3 or more DLTs level -1, with nivolumab 360mg on d4,36, surgery and MP with nivolumab on d210, ev 3 weeks up to d364.
intervention type: Drug
intervention name: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
other name: Sutent
intervention type: Drug
intervention name: Nivolumab 100 MG/10 ML [Opdivo]
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
other name: Opdivo
intervention type: Drug
intervention name: Epirubicin
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
intervention type: Drug
intervention name: Ifosfamide
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
intervention type: Drug
intervention name: Doxorubicin
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
intervention type: Drug
intervention name: Dacarbazine
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
intervention type: Drug
intervention name: Cisplatin
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
intervention type: Drug
intervention name: Methotrexate
description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
arm group label: Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS
criteria: 
gender: All
minimum age: 12 Years
maximum age: 80 Years
healthy volunteers: No
last name: Javier Martín Broto
role: Study Director
affiliation: Hospital Universitario Fundación Jiménez Díaz
last name: Andrés Redondo
role: Principal Investigator
affiliation: Hospital Universitario La Paz
last name: Claudia Valverde
role: Principal Investigator
affiliation: Hospital Universitari Vall d'Hebrón
last name: Antonio López Pousa
role: Principal Investigator
affiliation: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
last name: Roberto Diaz de Beveridge
role: Principal Investigator
affiliation: Hospital Universitario La Fe
last name: Javier Martínez Trufero
role: Principal Investigator
affiliation: Hospital Miguel Servet
last name: Irene Carrasco
role: Principal Investigator
affiliation: Hospitales Universitarios Virgen del Rocío
last name: Enrique González
role: Principal Investigator
affiliation: Hospital Universitario 12 de Octubre
last name: Josefina Cruz
role: Principal Investigator
affiliation: Hospital Universitario de Canarias
last name: Silvia Stacchiotti
role: Principal Investigator
affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
last name: Giovanni Grignani
role: Principal Investigator
affiliation: Candiolo Cancer Institute - FPO, IRCCS
last name: Emanuela Palmerini
role: Principal Investigator
affiliation: Istituto Ortopedico Rizzoli
last name: Sandra Strauss
role: Principal Investigator
affiliation: University College London Hospitals
last name: Cristina Mata
role: Principal Investigator
affiliation: Hospital General Universitario Gregorio Marañón
last name: Antonio Casado
role: Principal Investigator
affiliation: Hospital Clínico Universitario San Carlos
last name: Alejandro Pérez Fidalgo
role: Principal Investigator
affiliation: Hospital Clínico Universitario de Valencia
last name: Luis De Sande
role: Principal Investigator
affiliation: Hospital Universitario de León
last name: Alba Rubio
role: Principal Investigator
affiliation: Hospital Infantil Universitario Niño Jesús
last name: Jerónimo Martínez
role: Principal Investigator
affiliation: Hospital Universitario Virgen de la Arrixaca
last name: Patricio Ledesma
phone: +34 971439900
email: ensayos@sofpromed.com
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Italy
country: Spain
country: United Kingdom
responsible party type: Sponsor
mesh term: Sarcoma
mesh term: Osteosarcoma
mesh term: Doxorubicin
mesh term: Nivolumab
mesh term: Methotrexate
mesh term: Sunitinib
mesh term: Epirubicin
mesh term: Ifosfamide
mesh term: Dacarbazine